PE20130312A1 - Una combinacion antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino - Google Patents
Una combinacion antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platinoInfo
- Publication number
- PE20130312A1 PE20130312A1 PE2012002429A PE2012002429A PE20130312A1 PE 20130312 A1 PE20130312 A1 PE 20130312A1 PE 2012002429 A PE2012002429 A PE 2012002429A PE 2012002429 A PE2012002429 A PE 2012002429A PE 20130312 A1 PE20130312 A1 PE 20130312A1
- Authority
- PE
- Peru
- Prior art keywords
- derivative
- administered
- dose
- ombrabulin
- taxan
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 title abstract 2
- 229950003600 ombrabulin Drugs 0.000 title abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical class [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title abstract 2
- 190000008236 CARBOPLATIN Chemical compound 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 208000037844 advanced solid tumor Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229960004562 carboplatin Drugs 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) OMBRABULINA QUE SE ADMINISTRA A UNA DOSIS DE 15 A 35MG/M2; B) UN DERIVADO DE TAXANO TAL COMO PACLITAXEL QUE SE ADMINISTRA A UNA DOSIS DE 175 O 200MG/M2 O DOCETAXEL QUE SE ADMINISTRA A UNA DOSIS DE 60 O 75MG/M2; C) UN DERIVADO DE PLATINO TAL COMO CISPLATINO QUE SE ADMINISTRA A UNA DOSIS DE 75MG/M2 O CARBOPLATINO QUE SE ADMINISTRA A UNA DOSIS DE 5 O 6 AUC. DICHA COMBINACION ANTITUMORAL SE TOLERA BIEN, NO EXACERBA LA TOXICIDAD DE CADA UNO DE LOS AGENTES ANTITUMORALES Y ES UTIL EN EL TRATAMIENTO DE TUMORES SOLIDOS AVANZADOS ESTABILIZANDO O INDUCIENDO UNA REGRESION PARCIAL O COMPLETA DEL TUMOR
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10305653A EP2397135A1 (en) | 2010-06-18 | 2010-06-18 | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
| EP10306256A EP2481404A1 (en) | 2010-11-15 | 2010-11-15 | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130312A1 true PE20130312A1 (es) | 2013-03-26 |
Family
ID=45347705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002429A PE20130312A1 (es) | 2010-06-18 | 2011-06-16 | Una combinacion antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20130122113A1 (es) |
| EP (1) | EP2582369A1 (es) |
| JP (1) | JP2013528644A (es) |
| KR (1) | KR20130088753A (es) |
| CN (1) | CN103140224A (es) |
| AR (1) | AR082005A1 (es) |
| AU (1) | AU2011266635A1 (es) |
| BR (1) | BR112012031917A2 (es) |
| CA (1) | CA2802974A1 (es) |
| CO (1) | CO6650420A2 (es) |
| DO (1) | DOP2012000305A (es) |
| EA (1) | EA201291268A1 (es) |
| EC (1) | ECSP12012343A (es) |
| MA (1) | MA34380B1 (es) |
| MX (1) | MX2012014732A (es) |
| NI (1) | NI201200183A (es) |
| PE (1) | PE20130312A1 (es) |
| PH (1) | PH12012502483A1 (es) |
| SG (1) | SG186376A1 (es) |
| TN (1) | TN2012000552A1 (es) |
| TW (1) | TW201206419A (es) |
| UY (1) | UY33457A (es) |
| WO (1) | WO2011158206A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109851593B (zh) * | 2019-02-01 | 2021-04-16 | 沈阳药科大学 | 基于淋巴介导转运的甘油三酯前药及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW334418B (en) | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
| NZ507221A (en) | 1998-04-03 | 2003-04-29 | Ajinomoto Kk | Antitumor agent |
| US20020183266A1 (en) | 2001-03-15 | 2002-12-05 | Aventis Pharma, S.A. | Combination comprising combretastatin and anticancer agents |
| FR2838437B1 (fr) | 2002-04-11 | 2004-06-04 | Aventis Pharma Sa | Procedes de preparation de combretastatines |
| FR2945210B1 (fr) * | 2009-05-07 | 2011-07-01 | Sanofi Aventis | Combinaison antitumorale comprenant l'ave8062 et le sorafenib |
-
2011
- 2011-06-16 CA CA2802974A patent/CA2802974A1/en not_active Abandoned
- 2011-06-16 PH PH1/2012/502483A patent/PH12012502483A1/en unknown
- 2011-06-16 EP EP11738298.6A patent/EP2582369A1/en not_active Withdrawn
- 2011-06-16 MX MX2012014732A patent/MX2012014732A/es not_active Application Discontinuation
- 2011-06-16 PE PE2012002429A patent/PE20130312A1/es not_active Application Discontinuation
- 2011-06-16 MA MA35567A patent/MA34380B1/fr unknown
- 2011-06-16 WO PCT/IB2011/052628 patent/WO2011158206A1/en not_active Ceased
- 2011-06-16 KR KR1020127032877A patent/KR20130088753A/ko not_active Withdrawn
- 2011-06-16 CN CN2011800398329A patent/CN103140224A/zh active Pending
- 2011-06-16 AU AU2011266635A patent/AU2011266635A1/en not_active Abandoned
- 2011-06-16 SG SG2012092763A patent/SG186376A1/en unknown
- 2011-06-16 JP JP2013514831A patent/JP2013528644A/ja not_active Withdrawn
- 2011-06-16 BR BR112012031917A patent/BR112012031917A2/pt not_active IP Right Cessation
- 2011-06-16 EA EA201291268A patent/EA201291268A1/ru unknown
- 2011-06-17 AR ARP110102109A patent/AR082005A1/es unknown
- 2011-06-17 UY UY0001033457A patent/UY33457A/es unknown
- 2011-06-17 TW TW100121314A patent/TW201206419A/zh unknown
-
2012
- 2012-11-23 TN TNP2012000552A patent/TN2012000552A1/en unknown
- 2012-12-06 DO DO2012000305A patent/DOP2012000305A/es unknown
- 2012-12-07 NI NI201200183A patent/NI201200183A/es unknown
- 2012-12-18 CO CO12228676A patent/CO6650420A2/es not_active Application Discontinuation
- 2012-12-18 EC ECSP12012343 patent/ECSP12012343A/es unknown
- 2012-12-18 US US13/718,335 patent/US20130122113A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011158206A1 (en) | 2011-12-22 |
| BR112012031917A2 (pt) | 2017-11-28 |
| AU2011266635A1 (en) | 2013-01-10 |
| EA201291268A1 (ru) | 2013-04-30 |
| TW201206419A (en) | 2012-02-16 |
| US20130122113A1 (en) | 2013-05-16 |
| ECSP12012343A (es) | 2012-12-28 |
| CN103140224A (zh) | 2013-06-05 |
| AR082005A1 (es) | 2012-11-07 |
| TN2012000552A1 (en) | 2014-04-01 |
| NI201200183A (es) | 2013-05-13 |
| CO6650420A2 (es) | 2013-04-15 |
| CA2802974A1 (en) | 2011-12-22 |
| UY33457A (es) | 2012-01-31 |
| DOP2012000305A (es) | 2013-01-31 |
| KR20130088753A (ko) | 2013-08-08 |
| SG186376A1 (en) | 2013-01-30 |
| JP2013528644A (ja) | 2013-07-11 |
| PH12012502483A1 (en) | 2013-03-25 |
| EP2582369A1 (en) | 2013-04-24 |
| MA34380B1 (fr) | 2013-07-03 |
| MX2012014732A (es) | 2013-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125358T1 (el) | Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων | |
| CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
| CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
| ECSP20020410A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| CY1119714T1 (el) | Ενωσεις αναστολεων | |
| NI201300074A (es) | Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos. | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| EA201591363A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| MX2016008201A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
| BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| EA201792169A1 (ru) | 5'-замещенные нуклеозидные соединения | |
| GT201500312A (es) | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
| PE20121520A1 (es) | Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular | |
| MX370662B (es) | Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CL2016000026A1 (es) | Nuevos derivados de azabencimidazol | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| WO2016160621A3 (en) | Nk-92 cells in combination therapy with cancer drugs | |
| MX2018006953A (es) | Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer. | |
| CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
| TR201819805T4 (tr) | Flavaglin türevleri̇. | |
| PH12017502046A1 (en) | Salts and prodrugs of 1-methyl-d-tryptophan | |
| MX381102B (es) | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |